Anticancer research · 2025
c-MYC Protein Expression Patterns in Laryngeal-Hypopharyngeal Squamous Cell Carcinomas.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Papouliakos Sotirios, Chrysovergis Aristeidis, Papanikolaou Vasileios, Tsounis Dimitrios, Roukas Dimitrios, Rigopoulos Dimitrios, Papanastasiou George, Tsiambas Evangelos, Pantos Pavlos, Poulianitis Nikolaos, Lazaris Andreas C, Kavantzas Nikolaos, Kyrodimos Efthymios
Аннотация
BACKGROUND/AIM: Over activation of c-MYC oncogene (gene locus: 8q24.21) - predominantly due to the amplification of the gene - is a critical genetic imbalance involved in malignant transformation of normal epithelia. Our aim was to explore the differences in c-MYC protein expression in a series of laryngeal (LSCC) and hypopharyngeal squamous cell carcinomas (HPSCCs).
MATERIALS AND METHODS: We retrospectively analyzed a set of sixty (n=60) paraffin embedded laryngeal-hypopharyngeal squamous cell carcinomas (L-PHSCC) tissue sections by immunocytochemistry (IHC) for the detection of c-MYC protein expression. A digital image analysis (DIA) algorithm was also performed for measuring objectively the corresponding immunostaining intensity levels of the examined protein. The correlation of c-MYC protein expression levels with various clinicopathological characteristics was assessed.
RESULTS: High and moderate staining intensity levels of c-MYC protein expression were identified in 46/60 (76.6%) of the examined cases (21/60 and 25/60, respectively), whereas the rest of them demonstrated low expression values (14/60, 23.4%). c-MYC expression was significantly correlated with the anatomic location of the malignancies (p=0.03), with the stage of the disease (p=0.004), as well as with the grade of differentiation (p=0.049). Interestingly, c-MYC diffuse nuclear/cytoplasmic expression was observed mainly in advanced-stage carcinomas.
CONCLUSION: c-MYC overexpression is a common feature in L-HPSCCs, mainly due to c-MYC oncogene overactivation. Increased levels of nuclear and diffuse cytoplasmic c-MYC protein are associated with aggressive phenotypes in patients with L-HPSCCs. Given the emerging interest in oncogene-targeted therapies in modern oncology, identifying patients with distinct c-MYC genetic, epigenetic, and proteomic signatures represents a promising strategy for personalized treatment approaches.
MATERIALS AND METHODS: We retrospectively analyzed a set of sixty (n=60) paraffin embedded laryngeal-hypopharyngeal squamous cell carcinomas (L-PHSCC) tissue sections by immunocytochemistry (IHC) for the detection of c-MYC protein expression. A digital image analysis (DIA) algorithm was also performed for measuring objectively the corresponding immunostaining intensity levels of the examined protein. The correlation of c-MYC protein expression levels with various clinicopathological characteristics was assessed.
RESULTS: High and moderate staining intensity levels of c-MYC protein expression were identified in 46/60 (76.6%) of the examined cases (21/60 and 25/60, respectively), whereas the rest of them demonstrated low expression values (14/60, 23.4%). c-MYC expression was significantly correlated with the anatomic location of the malignancies (p=0.03), with the stage of the disease (p=0.004), as well as with the grade of differentiation (p=0.049). Interestingly, c-MYC diffuse nuclear/cytoplasmic expression was observed mainly in advanced-stage carcinomas.
CONCLUSION: c-MYC overexpression is a common feature in L-HPSCCs, mainly due to c-MYC oncogene overactivation. Increased levels of nuclear and diffuse cytoplasmic c-MYC protein are associated with aggressive phenotypes in patients with L-HPSCCs. Given the emerging interest in oncogene-targeted therapies in modern oncology, identifying patients with distinct c-MYC genetic, epigenetic, and proteomic signatures represents a promising strategy for personalized treatment approaches.